Cas:76769-55-6 DIPIVALOYL-L-TARTARIC ACID manufacturer & supplier

Chemical Name:DIPIVALOYL-L-TARTARIC ACID

CAS.NO:76769-55-6

Synonyms:Butanedioic acid, 2,3-bis(2,2-dimethyl-1-oxopropoxy)-, (2S,3S)-;MFCD00015634;DIPIVALOYL-L-TARTARIC ACID;(2S,3S)-2,3-Bis[(2,2-dimethylpropanoyl)oxy]succinic acid;(+)-dipivaloyl-d-tartaric acid

Molecular Formula:C₁₄H₂₂O₈

Molecular Weight:318.320

HS Code:2918990090

Physical and Chemical Properties:

Melting point:127-130 °C(lit.)

Boiling point:436.6±45.0 °C at 760 mmHg

Density:1.2±0.1 g/cm3

Index of Refraction:1.484

PSA:127.20000

Exact Mass:318.131470

LogP:3.74

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:NONH for all modes of transpor

Packing Group:

Contact us for information like Butanedioic acid, 2,3-bis(2,2-dimethyl-1-oxopropoxy)-, (2S,3S)- chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,(+)-dipivaloyl-d-tartaric acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,(2S,3S)-2,3-Bis[(2,2-dimethylpropanoyl)oxy]succinic acid Use and application,Butanedioic acid, 2,3-bis(2,2-dimethyl-1-oxopropoxy)-, (2S,3S)- technical grade,usp/ep/jp grade.

Related News: Today’s decisions represent progress in our continued efforts to make a difference in this pandemic on a global scale, Kathy Wengel, J&J’s chief global supply chain officer, said in the statement. DIPIVALOYL-L-TARTARIC ACID manufacturer Analysts at Jefferies, meanwhile, said the FDA accelerated approval for Aduhelm, which was based on a surrogate endpoint of amyloid beta plaque reduction (and not clinical benefit) “has implications for ongoing AD studies,” most notably, it reckons, for Roche’s phase 3 GRADUATE test for its anti-amyloid-beta candidate gantenerumab, “as a much lower hurdle than demonstrating clear cognitive benefit” has now become precedent. Jefferies, still cautious, said it remains “unclear what stance FDA may take for the field if GRADUATE fails on cognition despite significant Abeta reductions,” but says it’s probably not going to revive Roche-AC Immune’s anti-amyloid-beta candidate crenezumab, which saw its late-stage CREAD trials discontinued for futility but which is currently in an Alzheimer’s prevention study. DIPIVALOYL-L-TARTARIC ACID supplier Today’s decisions represent progress in our continued efforts to make a difference in this pandemic on a global scale, Kathy Wengel, J&J’s chief global supply chain officer, said in the statement. DIPIVALOYL-L-TARTARIC ACID vendor With the improvement of people’s living standards and the aging degree, the demand for medicines has been increasing for a long time. Therefore, the transfer from finished medicines to bulk medicines has greatly promoted the demand for bulk medicines. DIPIVALOYL-L-TARTARIC ACID factory Today’s decisions represent progress in our continued efforts to make a difference in this pandemic on a global scale, Kathy Wengel, J&J’s chief global supply chain officer, said in the statement.